Real-world study of everolimus in advanced progressive neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

http://www.wikidata.org/entity/Q33417013

about

How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Emerging use of everolimus in the treatment of neuroendocrine tumors.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases.Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea.Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

P2860

Q26750748-A8F8A5C1-ED02-416C-AE0D-B24327112E81 Q28081657-934C8262-C13C-4F24-8D13-95833406DED7 Q28087313-EB82F629-C1E7-4E4C-A020-303679A884FE Q36494977-25E306BF-646C-44E0-B740-D4A263745B02 Q36782339-84395555-3583-4D6D-982C-B85D24A2A967 Q37091117-4AD07187-76E2-4D53-AB15-212203E71FDF Q38331666-A0DDCAE1-E6FA-4C0D-A098-F0A9FA2B8D7C Q38494344-7817FB15-A4DC-4DC2-B61C-05C92AF65AD3 Q38527936-E83A6A30-946D-4BFA-9AE7-A4B112E4DAE9 Q38661603-B3EF6E32-434A-4816-88DD-21415FEB9F3E Q38730927-5A7A707A-20B9-47AE-9568-41E131DA76CF Q38835123-01C10EA0-138B-42E5-8230-42B69E6E31C1 Q38842250-84E1C1D5-7F6B-4F81-99AF-3AAF429645BA Q39201601-BF990359-F188-43BA-87D0-E6BD5B68486B Q40429391-C2515E20-058F-4C0D-833A-AF7EC1993DCE Q40975849-5CAE7885-3366-44CB-A8CD-184C011BD488 Q41139111-F1ABFB08-3DBF-47C5-9E19-D1CD6FB75D4E Q41559421-ABD3A867-35AD-4493-B253-BD158A209A20 Q42355574-C2603EBA-32D4-47B6-B580-A08D6EBBAB6E Q44062774-A6C54C18-A7D7-42AC-A444-97C6C683E901 Q48050451-A08F9D91-4B51-4569-B726-E495CA868A43 Q48252794-520FFCBE-418E-449C-9B44-9AA0B34F4A2C Q50201468-895B76A0-A571-4BA6-B269-047EC66393C4 Q53545250-1D711E8C-652C-4230-8126-E022DB796A99 Q53706060-C2B62F38-1ED3-472E-B276-DB0338D128DC Q53809725-D5B93DCA-D0B5-4DBA-BB8F-1C8A3AADE210 Q55460770-C82AA555-1CFF-4C5A-9D7C-CC4D7526DEA8

P2860

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

http://www.wikidata.org/entity/Q33417013

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@ast

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@en

type

label

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@ast

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@en

prefLabel

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@ast

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@en

P1433

Q33417013-79C516E1-367B-4C15-A8B4-D588D2B6C3FE

P1476

Q33417013-98A13EA0-9F49-4773-B5E1-21C0672123EB

P2093

Q33417013-087F2926-669D-436D-B953-1F7B6EBD8A69

Q33417013-10E2BB26-9D8D-4072-AC05-ECB83572D135

Q33417013-18475BC8-F84B-41D5-AE54-71441B9F0DE1

Q33417013-255D7882-12E5-4391-A9F3-8B498A7B07F5

Q33417013-47244433-D739-4903-8923-320B3376434C

Q33417013-55654175-FB86-4915-8147-551268F7A5AF

Q33417013-5C5F4846-7904-4911-A987-AEE3CFE53ECD

Q33417013-64628242-D86E-4BDF-835F-E113D1DCF997

Q33417013-66D8BFE9-53B5-4ADA-8AE0-AA10FA136F2B

Q33417013-6E78CE07-D28B-4403-AB60-60F4F561AE08

P2860

Q33417013-03F6F855-FDB5-474D-B9DC-99A2429D1AB3

Q33417013-1A46D859-05A0-4686-B3E6-85E70A47CEE9

Q33417013-29D5CD18-7FA8-4C98-862C-ABCDF76F0E18

Q33417013-2BDCB1FB-D23F-496B-81D0-BE66E309223B

Q33417013-36A63912-9737-4293-AB03-1893CE665F2D

Q33417013-378FD634-9B14-4AC8-A2BF-F745C6FD3EFB

Q33417013-45A020F4-F264-4A1F-83BF-02F4A84974D3

Q33417013-57390EE0-E22E-48A5-98B4-4CC1208192DB

Q33417013-5E75914C-CAE8-40CE-B0D7-453A8D0B5C6F

Q33417013-6359246D-8B0B-4F9B-A5BD-8E3216D5A3DE

P304

Q33417013-322EF1A5-728B-4EBF-8B55-AC2390049057

P31

Q33417013-A9931F9F-27E4-4C79-967D-B08093D03D68

P356

Q33417013-9A12A28F-3FC2-4D63-8A4F-9D3BB2310F85

P433

Q33417013-F372C85F-01C7-470E-B0CC-DAE5C695D8A1

P478

Q33417013-375E07D2-E040-45B0-BA83-92D343508EB9

P50

Q33417013-0AC2BF5D-9706-41D3-9F31-92A2B8D31953

Q33417013-285EF24A-A93D-4450-913F-70DECE7EA08D

Q33417013-339129F4-BE62-4185-A058-7868DDC73CFB

Q33417013-35E0CCB3-6B01-4EDE-A255-8BDC5E019ADE

Q33417013-4062EA20-5862-48AF-9596-32E83581F193

Q33417013-631E9DE1-A4FC-4C8E-92E2-4A8F2DB02D04

Q33417013-81A75DB7-4547-428D-9B60-A87A7C03C1F0

Q33417013-8D60CE41-529B-468D-B0BA-4B426BC3351D

Q33417013-948DE043-352B-4A93-B270-262073541FBE

Q33417013-97559263-1336-4F78-826D-16D82ABA40D4

P577

Q33417013-4DFA06A6-880B-485B-BB51-39AA90F11C2F

P5875

Q33417013-39FC0FD4-2B10-4FBA-B3E7-9E254E1A7F71

P698

Q33417013-3A61F229-E237-40C0-8457-0270E4AA5376

P932

Q33417013-77315077-83DC-4EBA-8E73-F023D9F5909F

P356

THEONCOLOGIST.2014-0037

P1433

P1476

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

@en

P2093

Alberto Zaniboni

http://www.w3.org/2001/XMLSchema#string

Alessandra Cassano

http://www.w3.org/2001/XMLSchema#string

Alfredo Berruti

http://www.w3.org/2001/XMLSchema#string

Annalisa Fontana

http://www.w3.org/2001/XMLSchema#string

Antongiulio Faggiano

http://www.w3.org/2001/XMLSchema#string

Carmen Nuzzo

http://www.w3.org/2001/XMLSchema#string

Chiara Funaioli

http://www.w3.org/2001/XMLSchema#string

Davide Pastorelli

http://www.w3.org/2001/XMLSchema#string

Elisabetta Nobili

http://www.w3.org/2001/XMLSchema#string

Ferdinando Riccardi

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Epidemiology of gastroenteropancreatic neuroendocrine tumours.

mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.

P304

966-974

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2014-0037

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Falconi

Maria Chiara Zatelli

Filippo de Braud

Stefano Cascinu

Francesco Panzuto

Giacomo Cartenì

P577

2014-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267749111

http://www.w3.org/2001/XMLSchema#string

P698

25117065

http://www.w3.org/2001/XMLSchema#string

P932

4153458

http://www.w3.org/2001/XMLSchema#string